Press Release

Printer Friendly VersionView printer-friendly version << Back



Audentes Therapeutics to Participate in Upcoming Investor Conferences

SAN FRANCISCO, Sept. 26, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that it will participate in the following investor conferences in October:  

  • Leerink Partners Roundtable Series: Rare Disease & Oncology
    Natalie Holles, President and Chief Operating Officer
    Format: Fireside Chat
    Tuesday, October 2, 2018, 9:30 am ET
    New York, New York
  • Chardan 2nd Annual Genetic Medicines Conference
    Matthew R. Patterson, Chief Executive Officer
    Panel: Genetic Medicines: Pre-Commercial, Manufacturing & Regulatory Strategies
    Tuesday, October 9, 2018, 12:10 pm ET

    Format: Fireside Chat
    Tuesday, October 9, 2018, 3:45 pm ET
    New York, New York

To access live webcasts of the fireside chats, please visit the Events & Presentations page within the Investors + Media section of the Audentes website.  Following each conference, a replay of the live webcast will be available on the Audentes website for approximately 30 days.  There is no webcast available for the Genetic Medicines: Pre-Commercial, Manufacturing & Regulatory Strategies panel at the Chardan 2nd Annual Genetic Medicines Conference.

About Audentes Therapeutics, Inc.
Audentes Therapeutics (Nasdaq: BOLD) is a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases.  We are currently conducting Phase 1/2 clinical studies of our lead product candidates, AT132 for the treatment of X-linked myotubular myopathy (XLMTM), and AT342 for the treatment of Crigler-Najjar syndrome.  We have two additional product candidates in development, including AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia (CASQ2-CPVT).  We are a focused, experienced and passionate team committed to forging strong, global relationships with the patient, research and medical communities.

For more information regarding Audentes, please visit www.audentestx.com.

Audentes Contacts:

Investor Contact:
Andrew Chang
415.818.1033
achang@audentestx.com 

Media Contact:
Katie Hogan
415.951.3398
khogan@audentestx.com

Audentes Therapeutics, Inc. (PRNewsfoto/Audentes Therapeutics, Inc.)

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/audentes-therapeutics-to-participate-in-upcoming-investor-conferences-300718850.html

SOURCE Audentes Therapeutics, Inc.